Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma

Journal of Clinical Virology

Volumn 55, Issue 1, 2012, Pages 34-39

  Chai, San Jiun ^a   Pua, Kin Choo ^b   Saleh, Amyza ^a   Yap, Yoke Yeow ^c   Lim, Paul V H ^d   Subramaniam, Selva Kumar ^e   Lum, Chee Lun ^f   Krishnan, Gopala ^g   Wan Mahiyuddin, Wan Rozita ^h   Teo, Soo Hwang ^a   Khoo, Alan S B ^h   Yap, Lee Fah ^a,g  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b HOSPITAL PULAU PINANG   (Malaysia)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^d Tung Shin Hospital   (Malaysia)

^e SARAWAK GENERAL HOSPITAL   (Malaysia)

^f Queen Elizabeth Hospital   (Malaysia)

^g UNIVERSITY OF MALAYA   (Malaysia)

^h INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

Author keywords

Diagnosis; Epstein Barr Virus; Metastasis; Nasopharyngeal carcinoma

Indexed keywords

BIOLOGICAL MARKER; VIRUS DNA;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPING COUNTRY; DISTANT METASTASIS; EARLY CANCER; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALAYSIA; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84865166901     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.05.017     Document Type: Article

References (32)

1. Razak A.R., Siu L.L., Liu F.F., Ito E., O'Sullivan B., Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010, 46:1967-1978.
2. Cao X.P., Lu T.X., Ye W.J., Cui N.J. Prospective study on long-term efficacy of external plus intracavitary radiotherapy on stage I-II nasopharyngeal carcinoma. Ai Zheng 2007, 26:204-207.
3. Leung T.W., Tung S.Y., Sze W.K., Wong F.C., Yuen K.K., Lui C.M., et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005, 27:555-565.
4. Xiao W.W., Han F., Lu T.X., Chen C.Y., Huang Y., Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:1070-1076.
5. Pua K.C., Khoo A.S.B., Subramaniam S.K., Ong K.A., Gopala Krishnan G., Shahid H., et al. Nasopharyngeal carcinoma database. Med J Malaysia 2008, 63:3.
6. El-Sherbieny E., Rashwan H., Lubis S.H., Choi V.J. Prognostic factors in patients with nasopharyngeal carcinoma treated in hospital Kuala Lumpur. Asian Pac J Cancer Prev 2011, 12:1739-1743.
7. Prasad U., Ablashi D., Pratha Kea. Problem of occult primary in nasopharyngeal carcinoma. Nasopharyngeal carcinoma: current concepts 1983, 11-15. University of Malaya Press, Kuala Lumpur. U. Prasad (Ed.).
8. O'Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:S118-S121.
9. Teo P.M., Kwan W.H., Lee W.Y., Leung S.F., Johnson P.J. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996, 77:2423-2431.
10. Tsang R.K., Vlantis A.C., Ho R.W., Tam J.S., To K.F., van Hasselt C.A. Sensitivity and specificity of Epstein-Barr Virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004, 26:598-602.
11. Low W.K., Leong J.L., Goh Y.H., Fong K.W. Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2000, 123:505-507.
12. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr Virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191.
13. Malaysian Cancer Statistics - data and figure, Peninsular Malaysia 2006 2006, National Cancer Registry, Ministry of Health Malaysia. Z.A. Omar, Z.M. Ali, N.S.I. Tamin (Eds.).
14. Malaysia Statistics Department Population distribution and basic demographic characteristics. Population and housing census 2000 2001, Malaysia Statistic Department, Kuala Lumpur.
15. Devi B.C., Pisani P., Tang T.S., Parkin D.M. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 2004, 13:482-486.
16. Strong E.W., Batsakis J.G., Cassisi N.J., Cooper J.S., Fleming I.D., Goepfert H., et al. Head and neck sites: pharynx. AJCC cancer staging manual 1997, 31-39. Lippincott-Raven, Philadelphia, New York. 5th ed. I.D. Fleming, J.S. Cooper, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, G.P. Murphy (Eds.).
17. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., et al. Quantification of plasma Epstein-Barr Virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470.
18. Leung S-f, Zee B., Ma B.B., Hui E.P., Mo F., Lai M., et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006, 24:5414-5418.
19. Kondo S., Horikawa T., Takeshita H., Kanegane C., Kasahara Y., Sheen T.S., et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci 2004, 95:508-513.
20. Shao J.Y., Li Y.H., Gao H.Y., Wu Q.L., Cui N.J., Zhang L., et al. Comparison of plasma Epstein-Barr Virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004, 100:1162-1170.
21. Chang K.P., Hsu C.L., Chang Y.L., Tsang N.M., Chen C.K., Lee T.J., et al. Complementary serum test of antibodies to Epstein-Barr Virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 2008, 44:784-792.
22. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., Harijadi, Fachiroh J., Paramita D.K., et al. Diagnostic value of measuring Epstein-Barr Virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005, 43:3066-3073.
23. Bortolin M.T., Pratesi C., Dolcetti R., Bidoli E., Vaccher E., Zanussi S., et al. Clinical value of Epstein-Barr Virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 2006, 233:247-254.
24. Leung S.F., Tam J.S., Chan A.T., Zee B., Chan L.Y., Huang D.P., et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr Virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004, 50:339-345.
25. Yang X., Goldstein A.M., Chen C.J., Rabkin C.S., Chen J.Y., Cheng Y.J., et al. Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 2006, 118:780-784.
26. Fan H., Nicholls J., Chua D., Chan K.H., Sham J., Lee S., et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr Virus. Int J Cancer 2004, 112:1036-1041.
27. Lo Y.M., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr Virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:5452-5455.
28. Chan A.T., Lo Y.M., Zee B., Chan L.Y., Ma B.B., Leung S.F., et al. Plasma Epstein-Barr Virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002, 94:1614-1619.
29. Le Q.T., Jones C.D., Yau T.K., Shirazi H.A., Wong P.H., Thomas E.N., et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr Virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 2005, 11:5700-5707.
30. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
31. Chou J., Lin Y.C., Kim J., You L., Xu Z., He B., et al. Nasopharyngeal carcinoma - review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30:946-963.
32. Agulnik M., Epstein J.B. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol 2008, 44:617-627.